Aeolus Pharmaceuticals Inc. (AOLS.OB) Strengthens Board of Directors With Oncology, Government Contracting and Financial Industry Veterans
5/21/2013 11:53:48 AM
More...
|
Aeolus Pharmaceuticals Inc. (AOLS.OB) Provides Investor Update on Passage of Pandemic All-Hazards Preparedness Act of 2013
3/14/2013 9:40:08 AM
More...
|
Aeolus Pharmaceuticals Inc. (AOLS.OB) Announces First Quarter Fiscal Year 2013 Financial Results
2/20/2013 9:15:12 AM
More...
|
Aeolus Pharmaceuticals Inc. (AOLS.OB) Announces $3.2 Million Private Placement Financing
2/20/2013 9:14:20 AM
More...
|
Aeolus Pharmaceuticals Inc. (AOLS.OB) Announces Fiscal Year 2012 Results
1/3/2013 8:38:23 AM
More...
|
Aeolus Pharmaceuticals Inc. (AOLS.OB)'s AEOL 10150 Supresses Overexpression of 31 Hypoxia-Related Genes Caused by Radiation Exposure
10/17/2012 9:07:31 AM
More...
|
Aeolus Pharmaceuticals Inc. (AOLS.OB) Provides Positive Update on FDA Meeting
9/6/2012 9:55:11 AM
More...
|
Aeolus Pharmaceuticals Inc. (AOLS.OB) Announces Third Quarter Fiscal Year 2012 Financial Results
8/15/2012 8:29:27 AM
More...
|
Aeolus Pharmaceuticals Inc. (AOLS.OB) Announces AEOL 10150 Diminishes Oxidative Stress and Nerve Damage Following Exposure to Nerve Agent
7/30/2012 9:25:59 AM
More...
|
Aeolus Pharmaceuticals Inc. (AOLS.OB) Announces AEOL 10150 Reduces Lung Damage After Neupogen(R) Treatment Following Radiation Exposure
6/1/2012 9:36:53 AM
More...
|
|